Until Robert L. Michel came along and founded The Dark Intelligence Group (DIG) two decades ago, the clinical laboratory industry and the anatomic pathology profession lacked a trustworthy source for information about the management and operations of medical laboratories. From its inception in 1995, The Dark Report quickly became the “go to” source of industry intelligence, innovations in lab management, and strategic market analysis.
This excellence in reporting has earned recognition from his peers. For example, twice Michel and The Dark Report have won national awards for best investigative reporting by the Specialty Information Publishers Association. In 2005, the award was for Michel’s coverage about how the anatomic pathology condominium laboratories (pod labs) operated by urologists and gastroenterologists came to be, who operated them, and how these owners marketed the AP condo labs to other physician groups. In 2009, Michel’s award for best investigative reporting resulted from his published interviews with Quest Diagnostics Incorporated when the company admitted that, for a period of 18 months, it had been reported inaccurate Vitamin 25(OH) D results because of problems with its laboratory-developed test methodology. The Dark Report’s story was picked up by The New York Times and was in the national news cycle for several days.
In his role as Editor-in-Chief, Michel brought unique capabilities to DIG and The Dark Report. His management training and diverse business experience—along with his skills as a concise writer and analyst—proved to be a winning combination for readers of The Dark Report. For that reason, Michel’s story has many intriguing elements.
Immediately prior to founding DIG, he had served in several executive positions for Nichols Institute based in Portland, Oregon, and San Juan Capistrano, California. This was during the time that Nichols Institute was an independent public lab company with annual revenues of about $280 million (prior to its acquisition by MetPath, Inc., now Quest Diagnostics Incorporated). He traveled extensively to many of the clinical lab business units owned by Nichols Institute in different regions of the United States and played a role in formulating effective market strategies in response to the emergence of closed-panel HMOs, capitated pricing, and full-risk managed care contracts, among other successful management initiatives.
Prior to his service at Nichols Institute, Michel served at three different Fortune 100 companies. These were Procter & Gamble, Centex Corporation, and Financial Corp. of America. Each was an opportunity to master new management techniques and apply them in different industries. Between these positions, he gained experience as an entrepreneur, having founded a real estate development firm and a general contracting company in the Southeastern United States.
Robert Michel earned a Bachelor of Arts degree in Economics at the University of California, Los Angeles, where he played rugby, a sport he participated in for another 22 years. He is a native of California and grew up in Santa Ana.
From the Volume XXV No. 17 – December 3, 2018 issue
Another long-established regional laboratory company is about to be acquired. On November 27, Boyce and Bynum Pathology Laboratories of Columbia, Mo., disclosed that it had entered an agreement to be acquired by Quest Diagnostics Inc. Notably, the press release about the agreement states that the anatomic pathology division, Boyce and Bynum Professional Services, Inc., and the
From the Volume XXV No. 17 – December 3, 2018 issue
IN RECENT DAYS, RUMORS HAVE SURFACED that UnitedHealthcare has begun to terminate the contracts it holds with a number of regional and non-national clinical laboratories.
This news surfaced just as The Dark Report went to press. Given its importance to the clinical laboratory industry, we wanted to alert lab executives and pathologists to this development as
From the Volume XXV No. 16 – November 13, 2018 issue
In recent weeks, Apple signed agreements with the nation’s two largest lab companies to make their lab test data available on Apple’s Health Record app. Laboratory Corporation of America was first to announce its agreement with Apple on Oct. 29. Quest Diagnostics issued its press release about its pact with Apple on Nov. 8. Apple says that
From the Volume XXV No. 15 – October 22, 2018 issue
Efforts to enroll one million veterans in a program to determine how genetic variations affect health is moving swiftly. Current enrollment is 700,000 veterans and the one million goal is expected to be reached by 2021. In 2011, the federal Department of Veterans Affairs instituted the VA Million Veterans Program (MVP).
MORE ON: Million Vets
Recently the VA extended
From the Volume XXV No. 15 – October 22, 2018 issue
In a time of shrinking lab budgets and falling prices for lab tests in the United States, how are the larger in vitro diagnostic (IVD) manufacturers doing? A look at third-quarter financial reports provides useful insights as to which segments within the IVD industry are doing better than others.
In alphabetical order, here’s a quick snapshot
From the Volume XXV No. 15 – October 22, 2018 issue
Many pathologists currently leading academic pathology programs and private pathology groups got some of their best business advice from Laurence J. Peterson, CPA. For more than 30 years, Peterson was involved in the operation of both clinical laboratories and anatomic pathology groups throughout the nation.
Peterson’s family reported that he died on December 25, 2017. He
From the Volume XXV No. 14 – October 1, 2018 issue
That’s all the insider intelligence for this report.
Look for the next briefing on Monday, October 22, 2018.
Have you caught the latest e-briefings from DARK Daily? If so, then you’d know about …
…a recent study that discovered “low-value” medical lab tests and other overused medical procedures led to $282 million in “wasted” healthcare spending in Washington State in
From the Volume XXV No. 14 – October 1, 2018 issue
HOW OFTEN IS A DEFUNCT LAB COMPANY IN THE NEWS? That was the odd development last week when it was announced that a U.S. District Court had entered a $1.4 million civil judgement against Calloway Laboratories, Inc., a toxicology lab company formerly based in Woburn, Mass., for business practices during the period May 2014 through
From the Volume XXV No. 14 – October 1, 2018 issue
IN RECENT DECADES, probably no sector of the U.S. healthcare system has seen the level of fraud and abuse that seems to pervade the clinical laboratory industry. The common perception is that illegal inducements between lab companies and referring physicians are rampant and federal prosecutors have failed to bring enough violators to justice to effectively
From the Volume XXV No. 13 – September 10, 2018 issue
News that a laboratory’s courier truck was high-jacked in broad daylight with patient specimens aboard puts the spotlight on whether the security practices labs use to protect drivers, vehicles, and the patient specimens they may be carrying are adequate. On Aug. 3 in Durham, N.C., a driver of a courier vehicle owned by Laboratory Corporation of
